06-01-06 Cofc

Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Issued Patent No.	**7,034,058** 10/634,641
Issued Date	**April 25, 2006**
Application Number	**10/634,641**
Filing Date	**August 4, 2003**
First Named Inventor	**TAKAHATA, KYOYA**
Group Art Unit	**1614**
Examiner Name	**Delacroix Muirhei, Cybille**
Total Number of Pages in This Submission: **4**	Attorney Docket Number: **ORIN-004**

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment / Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement
- ☐ Certified Copy of Priority Documents
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Assignment Papers *(for an Application)*
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s
- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) *(please identify below):*
  - **Petition for Certification of Correction (1 pg.)**
  - **Certificate of Correction (1 pg.)**
  - **Copy of Column 12 with Change (1 pg.)**
  - **Postcard**

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	**CAROL L. FRANCIS, 36,513** **BOZICEVIC, FIELD & FRANCIS, LLP**
Signature	Carol L. Francis
Date	**May 30, 2006**

Certificate
JUN 06 2006
of Correction

EXPRESS MAIL LABEL NO. EV 687 637 510 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JUN 06 2006

EXPRESS MAIL LABEL NO. EV 687 637 510 US

PETITION FOR CERTIFICATE OF CORRECTION		
	Attorney Docket	ORIN-004
	First Named Inventor	TAKAHATA, KYOYA
	Patent Number	7,034,058
	Issue Date	April 25, 2006
	Application Number	10/634,641
	Filing Date	August 4, 2003
Address to: Mail Stop DAC Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Title: *"ANTI-TUMOR PHARMACEUTICAL COMPOSITION COMPRISING N-VANILLYL FATTY ACID AMIDE"*	

Sir:

Transmitted herewith for filing is a Certificate of Correction for the above-identified patent. In *column 12, line 9, please replace "(C016)" with -- (C16) --.* Enclosed is a copy of column 12 showing the change.

It is believed that no fee is due since the error was made by the Patent and Trademark Office. However, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. § 1.20, which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815 order number ORIN-004.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

By: _____
Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Fax: (650) 327-3231

PTO/SB/44 (02-01)
Approved for use through 01/31/2004. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 7,034,058
DATED : April 25, 2006
INVENTOR(S) : TAKAHATA, KYOYA, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Column 12, line 9, please delete "(C016)" and replace with -- (C16) --

MAILING ADDRESS OF SENDER:

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303

PATENT NO. 7,034,058

No. of additional copies

EFFECT OF THE INVENTION

The present invention provides a pharmaceutical composition having an anti-tumor effect, in particular, an anti-melanoma effect and an anti-leukemia cell effect. In particular, the present invention provides an anti-tumor pharmaceutical composition having little side-effect to normal cells like capsaicin; having a high anti-tumor effect, in particular, an anti-melanoma effect and an anti-leukemia cell effect; and not having hotness, stimulus and proinflammatory effect.

It has been reported that capsaicin, which is a compound related to the N-vanillyl fatty acid amide of the present invention, has an anti-tumor effect both in vitro and in vivo, and both of the data obtained in vitro or in vivo are correlative (Eur J. Cancer. 1996 October; 32A(11): 1995–2003). Both of the N-vanillyl fatty acid amide of the present invention and capsaicin induce an apoptosis to suppress the growth of tumor cells, and have in common the vanillyl amine structure binding to a vaniloid receptor known as an in vivo receptor (A. Szallasi et.al., Life Sci., 47, 1399–1408 (1990)).

Taking this point into consideration, although the present specification does not state the in vivo data, it is apparent to those skilled in the art that the pharmaceutical composition will be effective in vivo.

The inevention claimed is:

1. A method for the treatment of melanoma or leukemia comprising administering to a patient in need thereof an effective amount of a N-vanillyl fatty acid amide of formula (1):



(1)

wherein —CO—R group represents a saturated or unsaturated fatty acid residue containing from 14 to 32 carbon atoms.

2. The method of claim 1, wherein the —CO—R group is a member selected from the group consisting of saturated fatty acid residues containing from 14 to 32 carbon atoms.

3. The method of claim 2, wherein the —CO—R group is a member selected from the group consisting of myristic acid residue (C14), palmitic acid residue (C016) and stearic acid residue (C18). (C16)

4. The method of claim 1, wherein the —CO—R group is a member selected from the group consisting of unsaturated fatty acid residues containing from 14 to 32 carbon atoms.

5. The method of claim 4, wherein the —CO—R group is a member selected from the group consisting of unsaturated fatty acid residues having from 1 to 3 double bonds and containing 18 carbon atoms and unsaturated (any acid residues having 4 or 5 double bonds and containing 20 carbon atoms.

6. The method of claim 5, wherein the —CO—R group is a member selected from the group consisting of oleic acid residue (C18:1), ricinoleic acid residue (C18:1), linoleic acid residue (C18:2), linolens acid residue (C18:3) and eleostearis acid residue (C18:3).

7. The method of claim 5, wherein the —CO—R group is a member selected from the group consisting of arachidonis acid residue (C20:4) and eicosapentaeaoic acid residue (C20:5).

8. The method of claim 4, wherein the —CO—R group is a member selected from the group consisting of unsaturated fatty acid residues having four or more double bonds and containing 22, 24, 26, 28 or 32 carbon atoms.

9. The method of claim 8, wherein thc —CO—R group is 4,7,10,13,16,19-docosahexaenoic acid residue (C22:6).

* * * * *